Group 1 - The company, 康方生物, announced a conditional agreement for a placement of 23.55 million shares at a price of HKD 149.54 per share, which represents approximately 2.62% of the existing share capital as of the announcement date [1] - The placement price reflects a discount of about 4.75% compared to the closing price of HKD 157.00 on August 27, 2025 [1] - The estimated total gross proceeds from the placement are approximately HKD 3.522 billion, with net proceeds expected to be around HKD 3.493 billion after deducting commissions and related expenses [1] Group 2 - The board was informed that Dr. 夏瑜 and Dr. 李百勇, as sellers, entered into a secondary placement agreement to sell a total of 3 million existing shares, representing about 0.33% of the total issued shares as of the announcement date [2]
康方生物拟配售2355万股一级配售股份